Safety and Activity of CTX130, a CD70-Targeted Allogeneic CRISPR-Cas9–Engineered CAR T-Cell Therapy, in Patients With Relapsed or Refractory T-Cell Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
Lancet Oncol 2024 Nov 28;[EPub Ahead of Print], SP Iyer, RA Sica, PJ Ho, A Prica, J Zain, FM Foss, B Hu, A Beitinjaneh, WK Weng, YH Kim, MS Khodadoust, AO Huen, LM Williams, A Ma, E Huang, A Ganpule, SD Nagar, P Sripakdeevong, EL Cullingford, S Karnik, ML Dequeant, JN Patel, XS He, Z Li, QA He, JH Mendonez, A Keegan, SM HorwitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.